Login / Signup

A cross-sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system.

Advaitaa RavipatiTejus PradeepAntonella Tosti
Published in: International journal of dermatology (2024)
Based on the FAERS, there has been a steady rise in AA cases, and monoclonal antibodies were the most frequently cited medication class tied to AA. With a dearth of literature on triggers and patient demographics, we sought to describe features of AA cases that could increase awareness and be used to improve future clinical outcomes in patients.
Keyphrases
  • newly diagnosed
  • ejection fraction
  • systematic review
  • adverse drug
  • patient reported outcomes
  • current status